This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 5 of 80 for:    "Dementia With Lewy Bodies"

"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"

This study has been completed.
National Institute on Aging (NIA)
Information provided by:
Mayo Clinic Identifier:
First received: December 1, 2009
Last updated: June 24, 2013
Last verified: June 2013

This research study is to examine the effects of the study medication Armodafinil in patients with dementia with Lewy bodies (DLB).

DLB is associated with memory and other thinking problems, excessive daytime sleepiness, hallucinations, delusions, apathy, and reduced quality of life.

One type of medication that could potentially improve daytime sleepiness, memory and thinking skills, hallucinations, delusions, apathy, and quality of life is known as a wake-promoting medication. Armodafinil is a wake-promoting medication that has been developed for treatment of patients with narcolepsy, sleep apnea, and other disorders which cause excessive daytime sleepiness.

The drug used in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study. However the FDA has allowed the use of this drug/device in this research study.

In this study, patients with DLB will receive daily oral Armodafinil tablets, and their response to treatment will be assessed over 12 weeks. This study does not involve any placebo medication, so all patients will receive Armodafinil treatment.

Condition Intervention Phase
Dementia With Lewy Bodies Drug: Armodafinil Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Mean Initial Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) [ Time Frame: baseline, 12 weeks ]

    The MWT measures the subject's ability to stay awake while sitting quietly in a chair. The test has 4 parts, each lasting 40 minutes if the subject is able to remain awake that long each time, and the parts are spaced apart in 2 hour intervals through the day.

    The subject is placed in a dim room, with the only source of light slightly behind the subject's head and out of his/her field of vision, and back and neck supported. During this time the subject is monitored with the same measures that are used in a standard overnight sleep study called a polysomnogram. The sleep latency, or time it takes the subject to fall asleep, will be recorded.

    In healthy people, the time it takes to fall asleep may be approximately 30 minutes on the test. More than 97% of people will take eight minutes or longer to fall asleep. Therefore, sleep latency that is less than eight minutes is considered to be abnormal.

Enrollment: 20
Study Start Date: November 2009
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
150-250 mg armodafinil by mouth daily
Drug: Armodafinil
150-250 mg armodafinil by mouth daily
Other Name: Nuvigil

Detailed Description:

In patients with DLB, the following aims/objectives will be addressed by comparing data on key measures at baseline and at 4 and 12 weeks of therapy:

Primary Aims - to test the hypotheses that armodafinil therapy at 150-250 mg every morning:

  • will result in improvement in excessive daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS) and Maintenance of Wakefulness Test (MWT) (Aim 1A)
  • will result in improvement in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) (Aim 1B)
  • will result in improvement in the Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC) (Aim 1C)
  • will be well-tolerated with no significant side-effects present (Aim 1D)

Secondary Aims - to test the hypotheses that armodafinil therapy at 150-250 mg every morning will result in improvement in:

  • cognition as measured by the Mini-Mental State Examination (MMSE) and other focused neuropsychological tests (Aim 2A)
  • neuropsychiatric morbidity, particularly apathy, depression, visual hallucinations, and delusions, as measured by the Neuropsychiatric Inventory (NPI) (Aim 2B)
  • functional status as measured by the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (Aim 2C)
  • patient and caregiver quality of life (QOL) as measured by the linear analog scale (LASA) (Aim 2D)

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of clinically possible or probable DLB using established criteria
  • Age 50-90 inclusive
  • Epworth Sleepiness Scale score of 8 or greater
  • MMSE score between 10 and 26 inclusive
  • No active medical disorder that could preclude participation in a drug treatment trial over a 12 week protocol
  • Stable medication regimen over previous four weeks
  • Absence of psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness
  • Absence of clinically significant primary sleep-related breathing disorder causing sleepiness as demonstrated by polysomnography (PSG) [ie, no significant upper airway resistance syndrome (UARS), obstructive sleep apnea (OSA), nor central sleep apnea (CSA) as reflected by a combined respiratory disturbance index (RDI) <15] OR adequate documentation of efficacy of treatment for UARS, OSA, and CSA
  • Caregiver that is with the patient at least 4 hours/day for at least 5 days per week
  • Patient and caregiver willing and able to participate in all study-related procedures
  • Patient is capable of giving informed consent, or if appropriate, has caregiver capable of giving consent on the subject's behalf.

Exclusion Criteria:

  • Does not fulfill criteria for clinically possible or probable DLB
  • Age <50 or >90
  • Women with intact uterus and not post-menopausal unless pregnancy test performed at screening is negative
  • Epworth Sleepiness Scale score less than 8
  • MMSE score <10 or >26
  • Active medical disorder that could preclude participation in a drug treatment trial over a 52 week protocol, such as:

    • Hypertension with BP readings exceeding 150 mm Hg systolic and 90 mm Hg diastolic
    • Hypersensitivity to modafinil, armodafinil, or any other conventional stimulants
    • Myocardial infarction or cerebral infarct over preceding year, stable or unstable angina, known symptomatic coronary artery disease
    • History of left ventricular hypertrophy or mitral valve prolapse
    • History of chronic or paroxysmal atrial fibrillation, chronic or paroxysmal atrial flutter, ventricular fibrillation, or ventricular tachycardia
    • History of cancer over preceding 1 year (excluding squamous or basal cell carcinoma of the skin)
    • History of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS)
    • Pulmonary disease requiring oral or inhalatory medications
    • Any other medical disorder considered by the study physicians as inappropriate for any wake-promoting medication
  • Medication regimen has not been stable over preceding four weeks
  • Concurrent use of lamotrigine or oxcarbazepine
  • Presence of over-the-counter and prescription psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness, such as:

    • Clonazepam > 1 mg/night
    • Seroquel > 100 mg/night
    • Zyprexa > 10 mg/night
  • Presence of another clinically-significant primary sleep disorder (eg, UARS, OSA, CSA) that is not being treated
  • Clinically significant abnormalities on screening ECG or laboratory tests
  • Patient or caregiver unwilling or unable to participate in all study-related procedures
  • Caregiver is not with patient at least 4 hours/day for at least 5 days/week
  • Patient or caregiver unwilling or unable to provide informed consent
  • CT or MRI evidence of a clinically significant structural lesion that could account for the participants dementia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01023672

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
National Institute on Aging (NIA)
Principal Investigator: Bradley F Boeve, MD Mayo Clinic
  More Information

Responsible Party: Bradley F. Boeve, MD, Mayo Clinic Rochester Identifier: NCT01023672     History of Changes
Other Study ID Numbers: 09-003438
R01AG015866 ( U.S. NIH Grant/Contract )
P50AG016574 ( U.S. NIH Grant/Contract )
Study First Received: December 1, 2009
Results First Received: June 24, 2013
Last Updated: June 24, 2013

Keywords provided by Mayo Clinic:
Dementia with Lewy Bodies
neuropsychiatric morbidity
quality of life

Additional relevant MeSH terms:
Lewy Body Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders
Neurodegenerative Diseases
Wakefulness-Promoting Agents
Central Nervous System Stimulants
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017